Efficacy of a low dose of thalidomide in advanced multiple myeloma-Reference-Cited by-同舟云学术

Efficacy of a low dose of thalidomide in advanced multiple myeloma

Published:2002-08-15 Issue:4 Volume:100 Page:1519-1519
ISSN:1528-0020
Container-title:Blood
language:en
Short-container-title:

Author:

Leleu Xavier¹,Magro Leonardo¹,Fawaz Abir¹,Bauters Francis¹,Facon Tierry¹,Yakoub-Agha Ibrahim¹

Affiliation:

1. Correspondence: I. Yakoub-Agha, Service des Maladies du Sang, CHU, 59037 Lille, France; e-mail: .

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/100/4/1519/1686577/h81602001508j.pdf

Reference3 articles.

1. Antitumor activity of thalidomide in refractory multiple myeloma.;Singhal;N Engl J Med.,1999

2. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM) [abstract].;Barlogie;Blood.,2000

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2014-08

2. Thalidomide: Chemistry, Therapeutic Potential and Oxidative Stress Induced Teratogenicity;Current Topics in Medicinal Chemistry;2012-07-01

3. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome;European Journal of Haematology;2012-01-04

4. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group;Leukemia Research;2010-10

5. Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development;Current Medicinal Chemistry;2009-09-01